Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

4.555 -0.045 (-0.98%)
Streaming Delayed Price Updated: 12:47 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark
Via Stocktwits
Vanda (VNDA) Q2 Revenue Rises 4%
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
A Glimpse of Vanda Pharma's Earnings Potential
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals
 
Via Benzinga
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts
 
Via Benzinga
Earnings Scheduled For February 13, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts
 
Via Benzinga
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process. 
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology. 
Via Benzinga
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
A regulator's decision drained the market's enthusiasm for the company. 
Via The Motley Fool
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets... 
Via Benzinga
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
What's Going On With Vanda Pharmaceuticals Shares Today?
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response. 
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
 
Via Benzinga
Topics Stocks
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
 
Via Benzinga
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal
Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning! 
Via InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024
VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.